Cost Comparison of Different Forms of Androgen Ablative Therapies in Metastatic Castration-Resistant Prostate Cancer in Canada

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.453
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer

Clinical Medicine Insights: Oncology
Oncology
2016English

Pcn346 - Disease Specific Cost Analysis of the Nonmetastatic Castration-Resistant Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer Health States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Patient Reported Outcomes in Metastatic Castration-Resistant Prostate Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide

Clinical Medicine Insights: Oncology
Oncology
2013English

Metastatic Castration-Resistant Prostate Cancer: The Emerging Continuum of Care

Journal of the Canadian Urological Association
OncologyUrology
2013English

The Contemporary Use of Radium-223 in Metastatic Castration Resistant Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2018English

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Mechanisms of Acquired Resistance to Androgen Receptor Targeting Drugs in Castration-Resistant Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2014English

Alkaline Phosphatase in Metastatic Castration-Resistant Prostate Cancer: Reassessment of an Older Biomarker

Future Oncology
MedicineCancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy